265
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

The Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Peripheral Arterial Disease in the Chinese Population

, , , , , , , , ORCID Icon, , & show all
Pages 373-384 | Received 21 Oct 2022, Accepted 05 Jan 2023, Published online: 10 Feb 2023

References

  • Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. doi:10.1038/nrgastro.2017.109
  • Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672–2682. doi:10.1002/hep.30251
  • Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.e1. doi:10.1053/j.gastro.2019.11.312
  • Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
  • Söderberg C, Stål P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51(2):595–602. doi:10.1002/hep.23314
  • Forlano R, Mullish BH, Nathwani R, Dhar A, Thursz MR, Manousou P. Non-alcoholic fatty liver disease and vascular disease. Curr Vasc Pharmacol. 2021;19(3):269–279. doi:10.2174/1570161118666200318103001
  • Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: state-of-The-art. World J Gastroenterol. 2014;20(37):13306–13324. doi:10.3748/wjg.v20.i37.13306
  • Murabito JM, Evans JC, Larson MG, Nieto K, Levy D, Wilson PW. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. Arch Intern Med. 2003;163(16):1939–1942. doi:10.1001/archinte.163.16.1939
  • Morley RL, Sharma A, Horsch AD, Hinchliffe RJ. Peripheral artery disease. BMJ. 2018;360:j5842. doi:10.1136/bmj.j5842
  • Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: national health and nutrition examination study, 1999 to 2004. Circulation. 2011;124(1):17–23. doi:10.1161/circulationaha.110.003954
  • Wang FM, Yang C, Ballew SH, et al. Ankle-brachial index and subsequent risk of incident and recurrent cardiovascular events in older adults: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2021;336:39–47. doi:10.1016/j.atherosclerosis.2021.09.028
  • Huang Y, Bi Y, Xu M, et al. Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese. Arterioscler Thromb Vasc Biol. 2012;32(9):2321–2326. doi:10.1161/atvbaha.112.252957
  • Ampuero J, Gallego-Durán R, Romero-Gómez M. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. Rev Esp Enferm Dig. 2015;107(1):10–6.
  • Zou Y, Li X, Wang C, et al. Association between non-alcoholic fatty liver disease and peripheral artery disease in patients with type 2 diabetes. Intern Med J. 2017;47(10):1147–1153. doi:10.1111/imj.13549
  • Liu S, Wang J, Wu S, et al. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: a prospective analysis. Metabolism. 2021;120:154779. doi:10.1016/j.metabol.2021.154779
  • Angulo P, Bugianesi E, Bjornsson ES, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145(4):782–9.e4. doi:10.1053/j.gastro.2013.06.057
  • Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17(10):2937–2944. doi:10.1681/asn.2006040368
  • Chinese Diabetes Society. Clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China (2022 edition). Zhonghua nei ke za zhi. 2022;61(1):12–50. Chinese. doi:10.3760/cma.j.cn112138-20211027-00751
  • Liu LS, Wu ZS, Wang JG, et al. 2018 Chinese guidelines for prevention and treatment of hypertension-A report of the Revision Committee of Chinese guidelines for prevention and treatment of hypertension. J Geriatr Cardiol. 2019;16(3):182–241. doi:10.11909/j.issn.1671-5411.2019.03.014
  • Joint Committee for Developing Chinese guidelines on P. Chinese guidelines on prevention and treatment of dyslipidemia in adults. Zhonghua xin xue guan bing za zhi. 2007;35(5):390–419. Chinese.
  • Farrell GC, Chitturi S, Lau GK, Sollano JD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007;22(6):775–777. doi:10.1111/j.1440-1746.2007.05002.x
  • Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889–919. doi:10.1007/s12072-020-10094-2
  • Alves-Cabratosa L, Elosua-Bayes M, García-Gil M, et al. Hypertension and high ankle brachial index: the overlooked combination. J Hypertens. 2019;37(1):92–98. doi:10.1097/hjh.0000000000001861
  • Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the cardiovascular health study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation. 1993;88(3):837–845. doi:10.1161/01.cir.88.3.837
  • Aboyans V, Ricco JB, Bartelink MEL, et al. ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763–816. doi:10.1093/eurheartj/ehx095
  • Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation. 2004;110(6):738–743. doi:10.1161/01.Cir.0000137913.26087.F0
  • He Y, Jiang Y, Wang J, Fan L, Li X, Hu FB. Prevalence of peripheral arterial disease and its association with smoking in a population-based study in Beijing, China. J Vasc Surg. 2006;44(2):333–338. doi:10.1016/j.jvs.2006.03.032
  • Chuang SY, Chen CH, Cheng CM, Chou P. Combined use of brachial-ankle pulse wave velocity and ankle-brachial index for fast assessment of arteriosclerosis and atherosclerosis in a community. Int J Cardiol. 2005;98(1):99–105. doi:10.1016/j.ijcard.2004.01.019
  • Wang Y, Li J, Xu YW, et al. Prevalence of peripheral arterial disease and correlative risk factors among natural population in China. Zhonghua xin xue guan bing za zhi. 2009;37(12):1127–1131. Chinese.
  • Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589–600. doi:10.1016/j.jhep.2016.05.013
  • Guleria A, Duseja A, Kalra N, et al. Patients with non-alcoholic fatty liver disease (NAFLD) have an increased risk of atherosclerosis and cardiovascular disease. Trop Gastroenterol. 2013;34(2):74–82. doi:10.7869/tg.2012.101
  • Liu Y, Liu C, Shi X, et al. Correlations of non-alcoholic fatty liver disease and serum uric acid with subclinical atherosclerosis in obese Chinese adults. J Diabetes. 2017;9(6):586–595. doi:10.1111/1753-0407.12441
  • Conte SM, Vale PR. Peripheral arterial disease. Heart Lung Circ. 2018;27(4):427–432. doi:10.1016/j.hlc.2017.10.014
  • Hong HC, Hwang SY, Ryu JY, et al. The synergistic impact of nonalcoholic fatty liver disease and metabolic syndrome on subclinical atherosclerosis. Clin Endocrinol. 2016;84(2):203–209. doi:10.1111/cen.12940
  • Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421–431. doi:10.7326/0003-4819-141-6-200409210-00007
  • Aday AW, Matsushita K. Epidemiology of peripheral artery disease and polyvascular disease. Circ Res. 2021;128(12):1818–1832. doi:10.1161/circresaha.121.318535
  • Golledge J, Ward NC, Watts GF. Lipid management in people with peripheral artery disease. Curr Opin Lipidol. 2019;30(6):470–476. doi:10.1097/mol.0000000000000638
  • Luo J, Xu L, Li J, Zhao S. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease. Eur J Gastroenterol Hepatol. 2015;27(3):193–199. doi:10.1097/meg.0000000000000254
  • Cai J, Xu M, Zhang X, Li H. Innate immune signaling in nonalcoholic fatty liver disease and cardiovascular diseases. Annu Rev Pathol. 2019;14:153–184. doi:10.1146/annurev-pathmechdis-012418-013003
  • Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014;83(6):E212–20. doi:10.1002/ccd.25387
  • Signorelli SS, Scuto S, Marino E, Xourafa A, Gaudio A. Oxidative stress in Peripheral Arterial Disease (PAD) mechanism and biomarkers. Antioxidants. 2019;8(9):367. doi:10.3390/antiox8090367
  • Britton KA, Mukamal KJ, Ix JH, et al. Insulin resistance and incident peripheral artery disease in the Cardiovascular Health Study. Vasc Med. 2012;17(2):85–93. doi:10.1177/1358863x11436195
  • Yang SL, Zhu LY, Han R, Sun LL, Li JX, Dou JT. Pathophysiology of peripheral arterial disease in diabetes mellitus. J Diabetes. 2017;9(2):133–140. doi:10.1111/1753-0407.12474
  • Caturano A, Acierno C, Nevola R, et al. Non-alcoholic fatty liver disease: from pathogenesis to clinical impact. Processes. 2021;9(1):135. doi:10.3390/pr9010135
  • Rinaldi L, Pafundi PC, Galiero R, et al. Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review. Antioxidants. 2021;10(2):270. doi:10.3390/antiox10020270
  • Li W, Liu J, Cai J, et al. NAFLD as a continuous driver in the whole spectrum of vascular disease. J Mol Cell Cardiol. 2022;163:118–132. doi:10.1016/j.yjmcc.2021.10.007
  • Tilg H, From EM. NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol. 2020;17(7):387–388. doi:10.1038/s41575-020-0316-6
  • Lonardo A, Sookoian S, Pirola CJ, Targher G. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism. 2016;65(8):1136–1150. doi:10.1016/j.metabol.2015.09.017
  • Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691–1705. doi:10.1136/gutjnl-2020-320622
  • Gao L, Zhao W, Liu Q, Qin M. Association between metabolic syndrome and peripheral arterial disease in elderly patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2021;14:4783–4789. doi:10.2147/dmso.S343441
  • Gentile S, Turco S, Guarino G, et al. Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. Diabetes Obes Metab. 2001;3(1):33–40. doi:10.1046/j.1463-1326.2001.00103.x
  • Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism. 2022;126:154925. doi:10.1016/j.metabol.2021.154925